Statera Biopharma, Inc. (STAB) |
|
0.0175 0.001 (4.17%)
|
03-31 15:42 |
|
Open: |
0.0144 |
Pre. Close: |
0.0168 |
|
High:
|
0.0175 |
Low:
|
0.0144 |
|
Volume:
|
69,555 |
Market Cap:
|
1(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:22:21 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 0.04 One year: 0.05 |
| Support: |
Support1: 0.01 Support2: 0.01 |
| Resistance: |
Resistance1: 0.03 Resistance2: 0.04 |
| Pivot: |
0.01  |
| Moving Average: |
MA(5): 0.01  MA(20): 0.01
MA(100): 0.06 MA(250): 0.15 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 13.6 %D(3): 11.1 |
| RSI: |
RSI(14): 39 |
| 52-week: |
High: 0.5 Low: 0.01 |
| Average Vol(K): |
3-Month: 1,004 (K) 10-Days: 351 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ STAB ] has closed above bottom band by 45.2%. Bollinger Bands are 64.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 40 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.02 - 0.02 |
0.02 - 0.02 |
|
Low:
|
0.01 - 0.01 |
0.01 - 0.01 |
|
Close:
|
0.02 - 0.02 |
0.02 - 0.02 |
|
Company Description |
|
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as expanding into fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. The company is based in Fort Collins, Colorado. |
Headline News |
Fri, 31 Mar 2023
Inovio Pharmaceuticals Inc. stock outperforms market on strong trading day - MarketWatch
Wed, 22 Mar 2023
Inovio Pharmaceuticals Inc. stock falls Wednesday, underperforms market - MarketWatch
Fri, 17 Mar 2023
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Wed, 15 Mar 2023
Statera Biopharma Signs Letter of Intent for Merger with Worksite Labs - GlobeNewswire
Thu, 09 Mar 2023
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Tue, 07 Mar 2023
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
55 (M) |
| Shares Float |
38 (M) |
|
% Held by Insiders
|
15.9 (%) |
|
% Held by Institutions
|
5 (%) |
|
Shares Short
|
775 (K) |
|
Shares Short P.Month
|
829 (K) |
Stock Financials |
|
EPS
|
-0.77 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.3 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-573.3 |
|
Return on Assets (ttm)
|
-23.9 |
|
Return on Equity (ttm)
|
-287 |
|
Qtrly Rev. Growth
|
183.5 |
|
Gross Profit (p.s.)
|
0.01 |
|
Sales Per Share
|
0.06 |
|
EBITDA (p.s.)
|
-0.38 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-12 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-0.03 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0.25 |
|
Price to Cash Flow
|
-0.08 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
